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OBJECTIVES: The aim of this study was to develop a strategy to identify adverse drug events associated with
drug-drug interactions by analyzing the prescriptions of critically ill patients.
METHODS: This retrospective study included HIV/AIDS patients who were admitted to an intensive care unit
between November 2006 and September 2008. Data were collected in two stages. In the first stage, three
prescriptions administered throughout the entire duration of these patients’ hospitalization were reviewed,
with the Micromedex database used to search for potential drug-drug interactions. In the second stage, a search
for adverse drug events in all available medical, nursing and laboratory records was performed. The probability
that a drug-drug interaction caused each adverse drug events was assessed using the Naranjo algorithm.
RESULTS: A total of 186 drug prescriptions of 62 HIV/AIDS patients were analyzed. There were 331 potential
drug-drug interactions, and 9% of these potential interactions resulted in adverse drug events in 16 patients;
these adverse drug events included treatment failure (16.7%) and adverse reactions (83.3%). Most of the
adverse drug reactions were classified as possible based on the Naranjo algorithm.
CONCLUSIONS: The approach used in this study allowed for the detection of adverse drug events related to
9% of the potential drug-drug interactions that were identified; these adverse drug events affected 26% of
the study population. With the monitoring of adverse drug events based on prescriptions, a combination of the
evaluation of potential drug-drug interactions by clinical pharmacy services and the monitoring of critically ill
patients is an effective strategy that can be used as a complementary tool for safety assessments and the
prevention of adverse drug events.
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’ INTRODUCTION
Critically ill patients are at high risk of adverse drug
events (ADEs) for several reasons, including the complexity
of their clinical conditions, which can involve pharmacokinetic
variations and concurrent treatment with multiple drugs (1).
These events can seriously affect patients’ evolution and fre-
quently complicate clinical management by increasing lengths
of hospital stay and medical costs (2,3).
An ADE has been defined as ‘‘any injury occurring during
the patient’s drug therapy and resulting either from appro-
priate care or from unsuitable or suboptimal care’’ and includes
adverse drug reactions (ADRs) during the recommended use
of a medication and any harm secondary to a medication
error (4).
There are several methods for detecting ADE. Spontaneous
reporting is the traditional approach for ADE detection and
is often used in systematic analyses of ADEs (5). However,
such monitoring has the disadvantage of being more vulner-
able to underreporting and lack of detail; this drawback
hampers analysis (6). Another method for ADE detection is
active surveillance based on focused and structured activity
that includes direct observation, patient chart audits and trigger
tools. This strategy is often used in pharmacovigilance studies
in the ICU (7).
A large proportion of ADRs are known and preventable,
and such reactions are often attributable to the coadministra-
tion of drugs with an established interaction (6). Recent publi-
cations have shown that many potential drug-drug interactions
(DDIs) can be identified using drug prescriptions (2,8).
HIV patients admitted to the ICU typically have multiple
comorbidities and require frequent and concurrent ther-
apeutic schemes in combination with antiretroviral drugs;
as a result, DDI risks are elevated for such patients (9).DOI: 10.6061/clinics/2018/e148
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In a previous study involving the use of two electronic data-
bases, we detected a high number of potential DDIs asso-
ciated with the prescriptions of critically ill HIV patients (10).
Although literature reports have revealed high estimates
of potential DDIs in critically ill patients, few studies have
correlated DDIs with clinically relevant ADEs. The aim of
this study was to evaluate a strategy to identify ADEs using
potential DDIs identified from the prescriptions of critically
ill HIV patients.
’ METHODS
This retrospective study included all adult HIV/AIDS
patients (X18 years of age) who were admitted to the ICU
at Evandro Chagas National Institute of Infectious Diseases
(INI) between November 2006 and September 2008 and
required mechanical ventilation. Patients participating in clinical
trials or patients with a length of ICU stay of less than
72 hours were excluded. This cohort was used because a high
number of contraindicated drug combinations and major
potential DDIs in this population had been identified in a
prior study (10).
We collected information about prescribed drugs, length of
ICU stay, ADEs and demographic/clinical data from both
medical records and the INI ICU’s database. Simplified
Acute Physiology Scores (SAPS II) were calculated to assess
the severity of acute illness (11).
Data were collected in two consecutive stages. In the first
stage, three prescriptions for each patient were analyzed at
the following time points: 1) 24 hours after admission to
the ICU; 2) the median length of hospitalization; and 3) the
patient’s ICU discharge or death. The administered drugs
were recorded at these time points, and potential DDIs
were evaluated using the Micromedex 2.0 (12) database. This
database can help identify DDIs and provides information
about their clinical consequences. In addition, in accordance
with Micromedex definitions, DDIs were classified based on
their mechanism of action (pharmacokinetic or pharmaco-
dynamic), severity (contraindicated, severe, moderate, mild
or unknown), level of evidence based on the quality of docu-
mentation (excellent, good, fair, poor, unlikely or unknown)
and time of onset (immediate or delayed).
For the purposes of this analysis, given the clinical relevance
of potential DDIs, only moderate, severe and contraindicated
interactions with a level of evidence classified as either excel-
lent or good were examined. Drug interactions present in
sedation protocols or in treatments for tuberculosis were not
considered in this analysis.
Potential interactions and other variables were recorded in
a standardized and tested form. Drugs involved in potential
DDIs were categorized according to their Anatomical Ther-
apeutic Chemical classification (ATC/DDD 2010) (13).
In the second stage of this study, a search for ADEs in
patients’ medical records was performed. Based on potential
DDIs identified in the prior stage and their clinical con-
sequences, we examined medical records to detect ADEs.
Data were obtained from medical and nursing notes and
from laboratory test results provided in patients’ medical
charts.
In addition, the probabilities that the identified ADEs were
caused by potential DDIs were assessed using the Naranjo
algorithm, a ten-item scored questionnaire used to classify
such events as ‘‘definite’’, ‘‘probable’’, ‘‘possible’’ or ‘‘doubtful’’.
In our study, to facilitate appropriate classification, we considered
each pair of drugs involved in an interaction, comorbidities
and other medications (14).
Data were entered into EpiData 3.1 and analyzed using
SPSS for Windows, version 16.0. Exploratory analyses of
demographic data, DDIs and ADEs were performed using
frequencies, medians and ranges.
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’ RESULTS
We analyzed the medical records of 62 HIV/AIDS patients
who required mechanical ventilation. These patients had
a median age of 37.5 years and were predominantly male
(72.6%). The median SAPS II was 56 points (range, 31-
91 points), and the length of stay in the ICU ranged from 3 to
122 days, with a median of 13 days. A total of 186 prescrip-
tions were analyzed, with a mean of 9 drugs per prescription.
For all analyzed prescriptions, 331 potential DDIs were
identified using the Micromedex database (Figure 1). The
predominant characteristics of these DDIs were moderate
interaction (74.0%), a delayed onset (63.7%), a pharmacoki-
netic mechanism (68.3%) and good scientific documentation
(65.9%). We found that 9% of the identified DDIs were
related to ADEs; 24 ADEs were identified in 16 patients
(Table 1). ADRs accounted for 83.3% of the identified ADEs
and were mostly classified as moderate and possible. There
were four cases (16.7%) of therapeutic failure; the most
common ADE was seizure during anticonvulsant treatment.
The combination of fluconazole and omeprazole was the
most frequent pair of drugs involved in DDIs and associated
with ADEs. In particular, this combination was thought to be
involved in 6 of the 24 ADEs; these ADEs were related to
elevated transaminase levels and diarrhea.
’ DISCUSSION
The results suggest that our approach for identifying
ADEs using potential DDIs is feasible. It was possible to
identify a high frequency of potential DDIs from prescrip-
tions; 9% of these potential DDIs resulted in ADEs and
affected 26% of the study population.
A higher percentage of patients with ADEs was observed
in this study (26%) than in prior investigations. Krahenbul-
Melcher et al. (15) reported a corresponding percentage of
less than 5%, whereas Reis and Cassiani (8) observed ADE-
related potential DDIs in 7% of critically ill patients. The
elevated frequency observed in our study is likely due to
the examination of a cohort of critically ill HIV patients. The
treatment of such patients with combinations of multiple
drugs and antiretrovirals presents the potential for DDIs,
an important cause of ADRs (16). The fact that four ADEs asso-
ciated with five clinically relevant DDIs involving anti-
retroviral drugs were identified in our study may demonstrate
the importance of the evaluation of therapeutic management
in these patients.
The percentage of therapeutic failures observed in our
study is similar to that observed by Reis and Cassiani (8),
who found that 17.5 to 19% of potential DDIs detected based
on the prescriptions of critically ill patients at a university
hospital were related to therapeutic failures.
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The probability of ADRs caused by a DDI was assessed
using the Naranjo algorithm. We observed that most of
the observed ADRs were classified as possible (80%); this
result was similar to that obtained by Bucs¸a (17), who
reported that 71.4% of ADRs related to DDIs were classified
as possible.
The Naranjo algorithm has proven to be useful for both
prospective and retrospective diagnoses of ADRs in ICU
patients (1,2). However, given the categories of causality
associated with this algorithm, many studies regard only
events categorized as having a probability greater than pos-
sible as ADRs (2). From this perspective, these results point
to the effectiveness of an ADR tracking method involving the
consideration of potential DDIs.
Given the complexity of the analyzed population and the
methodology that we used, our results should be evaluated
carefully. We analyzed a specific subgroup of critically ill
(HIV-infected) patients, and our results may not be applic-
able to other patients. Furthermore, retrospective data collection
based on chart review can generate bias due to incomplete
patient records. To minimize this potential bias, we used
medical and nursing notes as well as laboratory results to
identify ADEs. Another limitation is the small cohort included
in this study, although we sought to minimize this limitation
by analyzing 3 prescriptions per patient, resulting in 186 days
of observation.
Despite these limitations, the presented approach provides
improvements with respect to safety in pharmacotherapy for
critically ill patients in intensive care. This method also con-
tributes to improving knowledge of the occurrence of DDIs
and ADEs and their impacts on the outcomes of critically ill
patients by accounting for clinical complexity, polypharmacy
and other factors that hamper the detection and evaluation of
ADEs in these patients.
In conclusion, this method could be used to detect ADEs,
including therapeutic failures and ADRs; such events were
related to 9% of identified DDIs. Given the complexity of
ADE evaluation in ICU patients, the strategy of monitoring
ADEs by examining potential DDIs in prescriptions can be
effective for identifying and preventing relevant events in
critically ill patients, and this approach should be used as a
complementary tool in safety assessments.
Figure 1 - Flowchart of the study.
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Table 1 - Adverse drug events related to drug-drug interactions
in patients admitted to the ICU at INI (N=24).
Adverse drug event Drug-drug interaction N
Treatment
failure
Seizure Valproic acid ritonavir 3
Phenytoin rifampin
Phenytoin ritonavir
Acyclovirphenytoin
Ciprofloxacinphenytoin
Poor sedation Morphine rifampin 1
Fentanyl rifampin
Adverse
drug
reaction
Elevated
transaminase levels
Fluconazoleomeprazole 3
Fluconazoleprednisone
Diarrhea Fluconazoleomeprazole 3
Excessive sedation Fluconazolemidazolam 3
Clonazepam ritonavir
Oral bleeding* Pyrimethamine SMX/TMP** 2
Hypotension Amlodipinefluconazole 1
Depression Prednisone ritonavir 1
Hepatotoxicity Phenytoin acetaminophen 1
Hypertension Clarithromycinprednisone 1
Pancytopenia* Pyrimethamine SMX/TMP** 1
Cardiac arrest* Amiodarone fentanyl 1
Amiodarone rifampin
Clarithromycinfluconazole
Somnolence Risperidone ritonavir 1
Vomiting Diazepamphenytoin 1
Anxiety Clarithromycinprednisone 1
Total 24
* serious interactions
** sulfamethoxazole/trimethoprim
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